| Website | trivascular2.com |
| Category | BioTech |
| Phone | 707-543-8800 |
| Employees | |
| Description | Medical Devices |
| Total | $155M |
| Series A, 3/08 MPM Capital New Enterprise Associates Delphi Ventures Kearny Venture Partners | $65M |
| Series B, 11/09 New Enterprise Associates Delphi Ventures MPM Capital Kearny Venture Partners | $30M |
| Series C, 8/10 Pinnacle Ventures New Enterprise Associates Delphi Ventures MPM Capital Kearny Venture Partners | $60M |
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees.
TRIVASCULAR’s first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
